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Hypothyroidism Might Be Related to Breast Cancer 
in Post-Menopausal Women
Johannes L.P. Kuijpens,1 Ivan Nyklíčtek,2 Marieke W.J. Louwman,1 Tony A.P. Weetman,3
Victor J.M. Pop,4 and Jan-Willem W. Coebergh1,5
An association between breast cancer and thyroid (autoimmune) diseases or the presence of thyroid peroxi-
dase antibodies (TPOAb; a marker of thyroid autoimmune disease) has been suggested. However, little is known
about whether women with thyroid (autoimmune) diseases are at increased risk for developing breast cancer.
This cross-sectional and prospective cohort study investigated whether the presence of TPOAb or thyroid dys-
function is related to the presence or development of breast cancer. An unselected cohort of 2,775 women around
menopause was screened for the thyroid parameters thyrotropin (TSH), free thyroxine (FT4), and TPOAb dur-
ing 1994. Detailed information on previous or actual thyroid disorders and breast cancer, and on putative fac-
tors related to breast cancer and thyroid disorders, was obtained. Clinical thyroid dysfunction was defined by
both abnormal FT4 and TSH, and subclinical thyroid dysfunction by abnormal TSH (with normal FT4). A
TPOAb concentration  100 U/ml was defined as positive (TPOAb). The study group was linked with the
Eindhoven Cancer Registry to detect all women with (in situ) breast cancer (ICD-O code 174) diagnosed be-
tween 1958 and 1994. Subsequently, in the prospective study, all women who did not have breast cancer in
1994 (n  2,738) were followed up to July, 2003, and all new cases of (in situ) breast cancer and all cancer-re-
lated deaths were registered. Of the 2,775 women, 278 (10.0%) were TPOAb. At the 1994 screening, 37 women
(1.3%) had breast cancer. TPOAbs were (independently) related to a current diagnosis of breast cancer (OR 
3.3; 95% CI 1.3–8.5). Of the remaining women, 61 (2.2%) developed breast cancer. New breast cancer was re-
lated to: (1) an earlier diagnosis of hypothyroidism (OR  3.8; 95% CI 1.3–10.9); (2) the use of thyroid medica-
tion (OR  3.2; 95% CI 1.0–10.7); and (3) low FT4 (lowest tenth percentile: OR  2.3; 95% CI 1.2–4.6). In the first
3 years follow up, the relationship between FT4 and log-TSH was disturbed in women with a new breast can-
cer diagnosis. The presence of TPOAb was not related to breast cancer during follow-up. A direct relationship
between thyroid autoimmunity and breast cancer is unlikely. Hypothyroidism and low-normal FT4 are related




BREAST CANCER is a major public health problem, with acumulative incidence of 9% for women in The Nether-
lands, accounting for 10,000 new patients annually (1). Apart
from familial predisposition, occupational, and reproduc-
tive/hormonal factors (which have a weak association with
breast cancer), and probably alcohol use of 3 drinks a day,
no clinically important risk factors for breast cancer are
known (2–4).
Together with the thyroid, human breast tissue shares the
ability to take up circulating iodide (5), and a sodium/io-
dide symporter is expressed in lactation and in mammary
tumors (6). Also, alterations of iodide metabolism exist in
both the tumor and normal tissue of breast cancer patients
(5). These studies suggest a possible association between
breast cancer and alterations in iodine metabolism.
Moreover, a relationship between breast cancer and thy-
roid disorders (especially autoimmune thyroid disease) has
been suggested: greater volumes of the thyroid were found
in breast cancer patients (7,8), the prevalence of thyroid per-
oxidase antibodies (TPOAb, a marker for autoimmune thy-
roiditis) was increased (8–12), and various thyroid disorders
were more prevalent (10,12). In addition, the presence of
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TPOAb might have a positive effect on the prognosis of
women with breast cancer; women treated with surgery and
who were positive for TPOAb showed a better prognosis
than TPOAb-negative women (11). However, all of these
studies were performed in selected groups of patients
(women with either breast cancer or thyroid disorders) and
did not study prospectively the incidence of breast cancer in
relation to thyroid parameters (such as thyroid function test-
ing or TPOAb) in an unselected cohort. Very few data are
known regarding the question of whether women with thy-
roid dysfunction or TPOAb are at risk for the development
of breast cancer. One older study was unable to show an in-
creased incidence of breast cancer in patients with various
thyroid disorders (12). Therefore, in an unselected cohort of
women around menopausal age, we studied both cross-sec-
tionally and prospectively whether: (1) the presence of
TPOAb was associated with a diagnosis of breast cancer or
with the development of breast cancer; and (2) subclinical or
clinical thyroid dysfunction was more prevalent in women
with breast cancer or was associated with the development
of breast cancer, independently of known risk factors.
Subjects and Methods
Subjects
During 1994, all women aged between 47 and 54 years
(n  8,503; see Fig. 1) living in the city of Eindhoven were
invited to participate in the Eindhoven perimenopausal os-
teoporosis study (EPOS, a study to estimate the prevalence
of osteopenia and osteoporosis in perimenopausal women,
and to assess determinants of low bone mineral density)
(14,15). Informed consent was obtained from 5896 Caucasian
Dutch women (73%). In an at-random chosen cohort of 2,775
women (47% of the participants), thyroid function and
TPOAb testing were performed (Fig. 1).
Detailed gynecological (including obstetrical), endocrino-
logical, and general medical histories, as well as the use of
medication (including oral contraceptives and thyroid med-
ication (thyroxine replacement therapy or the use of thyro-
statica: carbimazol and strumazol), the use of alcohol, and
smoking habits were determined by paramedical assistants.
Venous blood samples for thyroid function testing were col-
lected in Vacutainer tubes (8 ml). In a recent paper, the ac-
tual daily intake of iodine in the region was proved to be
sufficient (16), whereas previously the daily intake of iodine
had appeared to be low-normal (17).
The Eindhoven Cancer Registry was founded in 1955 and
became part of the Comprehensive Cancer Center South in
1983. The registry covers the southeastern part of The
Netherlands, a region with 2.3 million inhabitants, includ-
ing the city of Eindhoven. The registry can be considered
as being “complete” since the early 1970s. In the region, the
national breast cancer screening program for women aged
from 50 to 69 years was implemented in the early 1990s.
About 80% of all women participate in this program, and
all hospitals and the radiotherapy institutes in the region
participate in the cancer registry. Breast cancer and in situ
carcinoma of the breast are registered according to the In-
ternational Classification of Diseases for Oncology (ICD):
ICD-O code 174. In addition, the estrogen receptor status
(positive or negative) was assessed in all women with
breast cancer.
Thyroid parameters
Thyroid parameters were assessed by the measurement of
free T4 (FT4; reference range 8–26 pmol/L; Abbott, North
Chicago, IL), thyroid-stimulating hormone (TSH; reference
range 0.4–6 mU/L; Abbott), and TPOAb (Autozyme Tab,
Cambridge Life Sciences, Cambridge, UK). The coefficients
of variation for FT4 were 6.8, 8.2, and 6.7% at concentrations
of 6.4, 18, and 30 pmol/L, respectively; those for TSH were
9.8, 4.8, 3.9, and 3.1% at concentrations of 0.06, 0.75, 6.8, and
30 mU/L, respectively; and that for TPOAb was 9.6% at a
concentration of 231 U/ml. Clinical thyroid dysfunction was
defined by the presence of both FT4 and TSH concentrations
outside the reference range, whereas subclinical thyroid dys-
function was defined by a TSH concentration outside the ref-
erence range, with FT4 within reference limits. The TPOAb
assay was standardized according to the International Ref-
erence Preparation for anti-TPO MRC 66/387. A TPOAb con-
centration of 99 U/ml was defined as positive (TPOAb).
Analysis
In 1994, the study group (n  2,775) was linked to the
Eindhoven Cancer Registry to determine all women with
previous (since 1958) or actual breast cancer or in situ carci-
noma of the breast. Women with no diagnosis of breast can-
cer in 1994 were followed up to July, 2003, and were linked
again to identify new cases of breast cancer (see Fig. 1). The
incidence date (date of diagnosis) was noted. Also, all
women who had died of cancer (all types) during follow up
were registered.
Two separate analyses (both at a univariate and a multi-
variate level) were performed. During the first analysis, the
relationship between breast cancer and putative determi-
nants, including thyroid parameters and TPOAb, was stud-
ied cross sectionally. All women without a diagnosis of
breast cancer at the time of screening were introduced in the
second analysis to study prospectively the relationship be-
tween a new diagnosis of breast cancer and putative risk fac-
tors (including thyroid parameters and TPOAb).
Statistical analysis was performed by using SPSS-11. Uni-
variate differences were determined using the Chi-square
test. In addition, multiple logistic regression analyses were
performed to examine whether thyroid-related and other
hormonal factors were associated with breast cancer, inde-
pendently of known risk factors. Factors with p  0.1 in the
univariate analysis, and factors known from the literature to
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FIG. 1. Flowchart of inclusion and participation of women
in this study.
be (possibly) related to breast cancer (positive family history,
nulliparity, early menarche, and estrogen or alcohol use),
were introduced into the model. Odds ratios (OR) with 95%
confidence intervals (95% CI) were calculated. Apart from
the subject’s own informed consent for the cohort study, per-
mission for linking up to the cancer registry was obtained
from the medical supervisory committee of the Compre-
hensive Cancer Center South, Eindhoven.
Results
The characteristics of the 2,775 women are presented in
Table 1. TPOAbs were present in 278 women (10.0%). The
number of women with breast cancer during the study pe-
riod as a whole was 98 (3.5%). Fifteen of these 98 women
(15.3%) were TPOAb. TPOAb women differed with re-
gard to smoking habits and the use of alcohol (Table 1). The
mean TSH concentration in TPOAb women was signifi-
cantly higher than in women without TPOAb (5.59 mU/L,
SD  11.14, versus 1.58 mU/L, SD  2.66; t test, t  5.678,
p  0.001); the mean FT4 concentrations in TPOAb women
were lower (14.3 pmol/L (SD  4.2) versus 15.4 pmol/L
(SD  2.4; t test, t  6.234, p  0.001). Subclinical thyroid
dysfunction was found in 7.3% of the women: 118 (4.6%) had
decreased TSH and 69 (2.7%) increased TSH and 18 women
(0.7%) had clinical thyroid dysfunction. Twelve showed over
hypo- and 6 overt hyperthyroidism. Both (subclinical and
clinical) thyroid dysfunction and the use of thyroid medica-
tion (thyroxine and thyrostatica) were more prevalent in
TPOAb women (Table 1).
Estrogen receptor status was known in 23 of the 98 cases
of breast cancer; of these, all 3 TPOAb women were posi-
tive for estrogen receptor and 18 of the 20 women without
TPOAb.
Cross-sectional study
At the time of the EPOS screening, 37 women (1.3%) had
a (previous or current) diagnosis of breast cancer. The mean
TSH and FT4 concentrations in women with a diagnosis of
breast cancer were similar to women without breast cancer
(TSH, 1.85 mU/L, SD  2.10, versus 1.99 mU/l (SD  4.54)
(t test, p  0.1); FT4: 15.5 pmol/L (SD  2.4) versus 15.3
pmol/L (SD  2.7) (t test, p  0.1)). The univariate analysis
revealed that the presence of TPOAb was significantly re-
lated to a diagnosis of breast cancer (OR 3.0; 95% CI 1.4–6.5).
No other factors were significantly related to breast cancer
(see Table 2). The factors shown in Table 2 were introduced
in the multiple logistic regression analysis. This analysis re-
vealed that the presence of TPOAb was independently re-
lated to a diagnosis of breast cancer at the time of screening
(OR  3.3; 95% CI 1.3–8.5); none of the other factors showed
a significant relationship to breast cancer.
Prospective study
The remaining 2738 women were followed up prospec-
tively until July 1, 2003 (Fig. 1); in total, 7 women died after
a diagnosis of cancer (all types taken together), and 226
women were lost to follow up, simply due to moving away
from the area. Sixty one women (2.2%) developed breast can-
cer. Breast cancer was diagnosed in 6 women at 1 year, in 8
women at 2 years, in 8 women at 3 years, in 11 women at 4
years, in 5 women at 5 years, in 9 women at 6 years, in 6
women at 7 years, and in 3 women at 8 years after the EPOS
screening, respectively. The women with a diagnosis of
breast cancer within 1 year of screening (n  6) were ex-
cluded from the analysis because signs or symptoms of
breast cancer might have been present at the time of screen-
ing. Self-reported hypothyroidism and the use of thyroid
medication in 1994 were associated with a previous diagno-
sis of breast carcinoma (including in situ) 1 year later (OR 
3.8; 95% CI 1.3–10.9, and OR  3.2; 95 %CI 1.0–10.7, respec-
tively). After exclusion of all women on thyroid medication,
women with breast cancer  1 year after screening had lower
levels of FT4 compared to those without breast cancer (t-test,
t  2.4; p  0.02). FT4 in the lowest tenth percentile (FT4
12.5 pmol/L) was associated with an increased risk of
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TABLE 1. CHARACTERISTICS OF WOMEN 47–54 YEARS OF AGE WITHOUT (TPOAb ; n  2,497) and with (TPOAb; n  278)
TPOAb at the Time of the EPOS Screening in 1994
TPOAb TPOAb
number (%) number (%)
Education (years) (n  1,997) 9.5 years (SD  2.5) 9.3 (SD  2.6)
Currently smoking (n  2,156) 701 (36.2) 56 (25.7) p  0.003
Alcohol use (at some time) (n  2,453) 2,207 (77.2) 178 (72.4) p  0.004
Parity (1 child) (n  2,459) 1,937 (87.5) 220 (89.4)
Mean number of children (n  2,775) 1.9 (SD  1.1) 1.9 (SD  1.0)
Estrogen use (at some time) (n  2,467) 1900 (85.5) 208 (84.6)
Thyroid medication (n  2,775) 40 (1.6) 12 (4.3) p  0.001
Menarche 13 years (n  2,431) 351 (16.0) 32 (13.2)
Ovariectomy (one or both) (n  2,436) 161 (7.3) 10 (4.1) p  0.045
Subclinical thyroid dysfunctiona (n  2,560) 107 (4.6) 52 (20.6) p  0.001
Clinical thyroid dysfunctionb (n  2,560) 9 (0.4) 9 (3.6) p  0.001
Positive family history of breast cancer (n  1,707) 320 (20.8) 30 (17.9)
Breast cancerc (n  2,775) 78 (3.0) 14 (5.4)
aSubclinical thyroid dysfunction: abnormal TSH, normal FT4.
bClinical thyroid dysfunction: both abnormal TSH and FT4.
cBreast cancer: previously (n  37) and during follow up (n  56)
breast cancer (OR  2.3; 95% CI 1.2–4.6). These women
showed concentrations of TSH within the normal range. Fig-
ure 2 shows the scatter plots of FT4 in relation with log-TSH
for women without breast cancer during follow up, for
women with breast cancer  3 years and for women with
breast cancer  3 years after screening, respectively. Women
with breast cancer 3 years had lower FT4 levels (72% had
FT4 below the median of 15.1 pmol/L for women without
breast cancer). Also, log-TSH and FT4 were not correlated in
these women (r  0.02; n.s.; see Fig. 2).
The presence of TPOAb in 1994 was not associated with
the development of new (in situ) breast carcinoma during the
follow-up period (OR  1.1; 95% CI 0.4–2.7). A significant
relationship between the use of estrogens and the develop-
ment of breast cancer was found (Table 2). It was not possi-
ble to distinguish between the type and dose of estrogens,
nor the duration of use. Multiple logistic regression analysis
showed that the use of estrogens (OR  4.5; 95% CI 1.1–18.7,
self-reported hypothyroidism (OR  4.1; 95% CI 1.4–12.0),
and low FT4 (OR  2.4; 95% CI 1.2–4.9) were independently
related to new breast cancer. Again, no association was found
between TPOAb and the development of breast cancer.
Discussion
This is the first prospective study to describe low levels of
FT4 as being an independent risk factor for the development
of breast cancer in an unselected cohort of peri- and post-
menopausal women. Also, hypothyroidism appeared to be
associated with an increased risk for the development of
breast cancer. In addition, we showed that the presence of
TPOAb was more prevalent in women with a current or pre-
vious diagnosis of breast cancer. However, in a prospective
study, we found that the presence of TPOAb was not related
to the development of breast cancer.
In The Netherlands, the prevalence of TPOAb in women
aged from 20 to 55 years is 10–13%, which is similar to that
in other western countries (14,18–21). The prevalence of
TPOAb in women with breast cancer was 15.2%, which is in
agreement with the studies of Giani et al. and Rasmusson 
et al. (9,10). However, Shering et al. and Smyth et al. found
higher percentages of TPOAb positivity (up to 34% com-
pared to 18% in controls) (8,11). This is probably the result
of the use of a more sensitive TPOAb test or because of the
use of different cut-off points for elevated TPOAb concen-
trations. The point-prevalence of untreated thyroid dysfunc-
tion (for both hyper- and hypothyroidism) was 0.7%; it is not
known whether these women had any signs or symptoms 
of thyroid dysfunction. TPOAb women had significantly
higher concentrations of TSH. This is in agreement with the
results of various other studies that showed that women with
elevated TSH, alone or in combination with TPOAb, are at
high risk for developing (clinical) hypothyroidism (18,19,22).
Both the incidence of breast cancer (including in situ car-
cinoma) of 278/100,000/year (61 new cases in an 8-year fol-
low up of 2,739 women) and the cumulative incidence of
3.5% (98 cases in 2,775 women with a mean age of 60 years)
were in accordance with the regional incidence (about 274/
100,000 per year in women aged from 55 to 60 years) (1).
An association between the presence of TPOAb and breast
cancer was also found by various other authors (5,7,9,10,12).
However, these studies were cross sectional and were per-
formed in selected populations (e.g., in patients already di-
agnosed as having breast cancer), and therefore it was not
possible to establish a possible etiological relationship. In the
prospective part of our study, we showed that the develop-
ment of breast cancer was not related to the presence of
TPOAb, alone or in combination with high concentrations of
TSH, during an 8-year follow-up period. Therefore, we ar-
gue that a relationship between thyroid autoimmunity and
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TABLE 2. UNIVARIATE ANALYSIS OF RISK ESTIMATES OF FACTORS POSSIBLY ASSOCIATED WITH BREAST CANCER
Cross sectionala Prospectiveb
OR (95%CI) OR (95%CI)
Alcohol use 0.7 (0.4–1.7) 1.3 (0.7–2.2)
Smoking 1.4 (0.7–2.8) 1.0 (0.5–1.8)
Parity 1 1.2 (0.4–3.3) 1.3 (0.5–3.2)
Estrogen usec 1.4 (0.5–4.1) 4.1 (1.0–16.7)
Menarche 13 years 1.0 (0.5–1.9) 1.0 (0.6–1.9)
Positive family history of breast cancer 2.0 (0.8–4.7) 1.3 (0.6–2.9)
Subclinical thyroid dysfunction 1.2 (0.7–2.1) 1.9 (0.8–4.9)
Clinical thyroid dysfunction Too few cases Too few cases
Thyroid medication 1.0 (0.5–1.8) 3.2 (1.0–10.7)
Low FT4d 0.8 (0.2–2.6) 2.3 (1.2–4.6)
Low TSHe 1.6 (0.6–4.1) 2.9 (1.5–5.7)
TPOAbf 3.0 (1.41–6.46) 1.1 (0.4–2.7)
Two separate analyses were performed: cross-sectional (n  2,775; 37 women with previous breast cancer included) and
prospective (n  2,738; 56 women with new breast cancer included).
aCross-sectional: at the time of screening in 1994.
bProspective: during the follow up, 1994–July, 2002.
cEstrogen use: at some time, including OACs.
dLow FT4: 10 percentile, women on thyroid medication excluded.
eLow TSH:  10 percentile, women on thyroid medication excluded.
fTPOAb: positive for thyroid peroxidase antibodies in 1994.
breast cancer is unlikely. This is in conformity with the find-
ings of Hedley et al. who, in a prospective study (with a fol-
lowup of 1–11 years) of 2,523 patients with various thyroid
disorders (mostly autoimmune diseases), found no indica-
tions for an increased risk of breast cancer (13).
What is the explanation for the association between
TPOAb and breast cancer at a cross-sectional level? The pres-
ence of TPOAb (without increased TSH) is probably the first
sign of an irradiation- and/or chemotherapy-induced thy-
roiditis triggering an autoimuune reaction (23). Also, an 
immune response of the tumor itself might explain the pres-
ence of TPOAb. Thyroid dysfunction (especially hypothy-
roidism) during the long-term follow up for cancers of the
head and neck region and the breast has been described by
several authors (24–27). The cumulative incidence of (sub-
clinical) hypothyroidism was about 50% after a 20-year fol-
low-up period (25,26.). It might be suggested that women
treated for breast cancer with radiotherapy alone or in com-
bination with chemotherapy should have routine thyroid
function testing during follow up. Another explanation is
that the stress of a breast cancer diagnosis has effect on the
immune system (14).
Both self-reported hypothyroidism (OR  3.8; 95% CI
1.3–10.9) and the use of thyroid medication (OR  3.2; 95%
CI 1.0–10.7) were associated with an increased risk of breast
cancer. Smyth also suggested an association between hy-
pothyroidism (irrespective of thyroid autoimmunity) and
breast cancer (28). However, there is still no explanation for
this possible association. Is seems unlikely that thyroid med-
ication is a risk factor for the development of breast cancer
because, in the majority of cases, this medication consisted
of L-thyroxine replacement therapy. Thyrostatic drugs might
be carcinogenic. However, to be able to establish a causative
relationship, the follow-up period appeared to be too short.
Also, in our study, we found no relationship between self-
reported hyperthyroidism and breast cancer.
We have found that low levels of FT4 (within the tenth
percentile; 12.5 pmol/L) were associated with an increased
risk for breast cancer (OR  2.3; 95% CI 1.2–4.6). This asso-
ciation appeared to be independent of thyroid autoimmu-
nity, due to the absence of a relationship with TPOAb posi-
tivity and high or elevated levels of TSH (as a sign of
decreased thyroid reserve). Also, we found indications of a
mild disturbance of the relationship of FT4 and log-TSH in
the first 1–3 years of the follow-up period (Fig. 2B). Several
explanations for these findings can be suggested: Some of
the women at risk for breast cancer could also have a dif-
ferent set point for their thyroid (relatively low FT4 in com-
bination with low-normal TSH) without any clinical signs
(29). There may be a combined genetic predisposition for hy-
pothyroidism or low FT4 and breast cancer may exist (28),
or an as yet not diagnosed but detectable breast carcinoma
might lead to a mild form of non-thyroidal illness syndrome
(30), or an environmental or dietary factor (such as deficient
intake of iodine) may be involved (28).
In a small group of breast cancer patients, we found no
relationship between TPOAb and the presence of estrogen
receptors in the tumor. This was also the finding of Giani et
al. (10). However, our results are not conclusive because of
the small numbers.
Some limitations of this study should be mentioned. In-
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FIG. 2. Scatter plots of FT4 and log-TSH (women on thy-
roid medication excluded). (A) Women who never had
breast cancer. (n  2404; r  0.34, p  0.001). (B) Women
with breast cancer diagnosed 1–3 years after screening (n 
21; r  0.02, n.s.). (C) Women with breast cancer  3 years




formation regarding self-reported thyroid dysfunction and
medication use might have biased the results of our study.
Although the possible role of confounding factors was in-
vestigated by using multiple logistic regression analysis, in
which other factors known from the literature to be related
to breast cancer were included, it is still possible that the re-
lationship between breast cancer and TPOAb, at a cross-sec-
tional level, is mediated by an unknown factor. Moreover,
we did not evaluate the development of TPOAb in the fol-
low-up period prospectively, although the number of
women who might develop elevated TPOAb levels during
a 7-year follow-up period will be rather low. Epidemiologi-
cal studies in the Netherlands have shown that the preva-
lence of TPOAb in women remained stable at around 10%
as from about 20 years of age (20). Another limitation to this
study is the relatively short follow-up period: New breast
cancer resulting from TPOAb may not be detectable after a
maximum of only 7 years. Finally, other indices of autoim-
munity in relation to the development of breast cancer were
not taken into account.
In any future research, prospective studies should be per-
formed to evaluate whether the presence of TPOAb devel-
ops before or after the development of (detectable) breast
cancer. Moreover, studies to clarify the origins of TPOAb in
breast cancer patients, their potential effect on the progno-
sis of breast cancer, and their effect on thyroid function
should be performed.
Conclusions
A relationship may exist between low levels of FT4 and
the detection of breast cancer in peri- and postmenopausal
women. The presence of TPOAb is a marker for the presence
of breast cancer. A direct association between thyroid au-
toimmunity and breast cancer is unlikely. Further studies are
needed to clarify the origins of the possible relationship be-
tween low FT4 and breast cancer.
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